BR112015004578A2 - métodos para fornecer tratamento adjuvante a um paciente com uma diagnose anterior de melanoma que foi ressectado e para aumentar sobrevivência sem recaída (rfs) de um paciente depois de ressecção de melanoma, e, composição - Google Patents
métodos para fornecer tratamento adjuvante a um paciente com uma diagnose anterior de melanoma que foi ressectado e para aumentar sobrevivência sem recaída (rfs) de um paciente depois de ressecção de melanoma, e, composiçãoInfo
- Publication number
- BR112015004578A2 BR112015004578A2 BR112015004578A BR112015004578A BR112015004578A2 BR 112015004578 A2 BR112015004578 A2 BR 112015004578A2 BR 112015004578 A BR112015004578 A BR 112015004578A BR 112015004578 A BR112015004578 A BR 112015004578A BR 112015004578 A2 BR112015004578 A2 BR 112015004578A2
- Authority
- BR
- Brazil
- Prior art keywords
- patient
- melanoma
- rfs
- free survival
- resected
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
1 / 1 resumo âmãtodos para fornecer tratamento adjuvante a um paciente com uma diagnose anterior de melanoma que foi ressectado e para aumentar sobrevivãncia sem recaãda (rfs) de um paciente depois de ressecãão de melanoma, e, composiããoâ a presente invenã§ã£o refere-se a um mã©todo de fornecer tratamento adjuvante para um paciente humano, que compreende administrar em um paciente como essas doses terapeuticamente efetivas de dabrafenib e trametinib por um perãodo de tempo suficiente para aumentar sobrevivãªncia sem recaãda (rfs).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261696375P | 2012-09-04 | 2012-09-04 | |
PCT/US2013/057432 WO2014039375A1 (en) | 2012-09-04 | 2013-08-30 | Method of adjuvant cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112015004578A2 true BR112015004578A2 (pt) | 2017-07-04 |
Family
ID=50237545
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015004578A BR112015004578A2 (pt) | 2012-09-04 | 2013-08-30 | métodos para fornecer tratamento adjuvante a um paciente com uma diagnose anterior de melanoma que foi ressectado e para aumentar sobrevivência sem recaída (rfs) de um paciente depois de ressecção de melanoma, e, composição |
Country Status (21)
Country | Link |
---|---|
US (6) | US20150216868A1 (pt) |
EP (2) | EP3981408A1 (pt) |
JP (3) | JP2015527374A (pt) |
KR (1) | KR102134585B1 (pt) |
CN (2) | CN104582706A (pt) |
AU (2) | AU2013313050A1 (pt) |
BR (1) | BR112015004578A2 (pt) |
CA (1) | CA2882437C (pt) |
CY (1) | CY1124812T1 (pt) |
DK (1) | DK2892535T3 (pt) |
ES (1) | ES2900825T3 (pt) |
HK (1) | HK1206642A1 (pt) |
HR (1) | HRP20211817T1 (pt) |
HU (1) | HUE056646T2 (pt) |
IN (1) | IN2015KN00449A (pt) |
LT (1) | LT2892535T (pt) |
PL (1) | PL2892535T3 (pt) |
PT (1) | PT2892535T (pt) |
RU (1) | RU2640180C2 (pt) |
SI (1) | SI2892535T1 (pt) |
WO (1) | WO2014039375A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3981408A1 (en) | 2012-09-04 | 2022-04-13 | Novartis AG | Dabrafenib and trametinib in a method of adjuvant cancer treatment |
CA2934822A1 (en) | 2013-12-28 | 2015-07-02 | Guardant Health, Inc. | Methods and systems for detecting genetic variants |
CA3057969A1 (en) * | 2017-05-02 | 2018-11-08 | Novartis Ag | Combination therapy |
US11890286B2 (en) * | 2018-04-17 | 2024-02-06 | The University Of Chicago | Methods and compositions for treating cancer |
CN109106893B (zh) * | 2018-11-12 | 2021-04-20 | 上海市中西医结合医院 | 一种调节肠道屏障功能的中药复方制剂及其制备方法 |
WO2023105286A1 (en) | 2021-12-06 | 2023-06-15 | My Personal Therapeutics Ltd | A combination treatment for cancer |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS52670B (en) | 2004-06-11 | 2013-06-28 | Japan Tobacco Inc. | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PIRIDO (2,3-D) PYRIMIDINE DERIVATIVES AND SIMILAR COMPOUNDS FOR CANCER TREATMENT |
CA3054535A1 (en) * | 2005-02-18 | 2006-08-24 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
UA103319C2 (en) * | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
HUE060206T2 (hu) * | 2009-10-16 | 2023-02-28 | Novartis Ag | MEK gátlót és B-Raf gátlót tartalmazó kombináció |
US20130004481A1 (en) * | 2011-01-12 | 2013-01-03 | Boehringer Ingelheim International Gmbh | Anticancer therapy |
EP3981408A1 (en) | 2012-09-04 | 2022-04-13 | Novartis AG | Dabrafenib and trametinib in a method of adjuvant cancer treatment |
-
2013
- 2013-08-30 EP EP21190550.0A patent/EP3981408A1/en active Pending
- 2013-08-30 IN IN449KON2015 patent/IN2015KN00449A/en unknown
- 2013-08-30 CN CN201380046144.4A patent/CN104582706A/zh active Pending
- 2013-08-30 LT LTEPPCT/US2013/057432T patent/LT2892535T/lt unknown
- 2013-08-30 CN CN201710300645.0A patent/CN107308164A/zh active Pending
- 2013-08-30 AU AU2013313050A patent/AU2013313050A1/en not_active Abandoned
- 2013-08-30 RU RU2015105821A patent/RU2640180C2/ru active
- 2013-08-30 HU HUE13835019A patent/HUE056646T2/hu unknown
- 2013-08-30 SI SI201331951T patent/SI2892535T1/sl unknown
- 2013-08-30 PL PL13835019T patent/PL2892535T3/pl unknown
- 2013-08-30 KR KR1020157008387A patent/KR102134585B1/ko active IP Right Grant
- 2013-08-30 DK DK13835019.4T patent/DK2892535T3/da active
- 2013-08-30 CA CA2882437A patent/CA2882437C/en active Active
- 2013-08-30 BR BR112015004578A patent/BR112015004578A2/pt not_active IP Right Cessation
- 2013-08-30 EP EP13835019.4A patent/EP2892535B1/en active Active
- 2013-08-30 ES ES13835019T patent/ES2900825T3/es active Active
- 2013-08-30 PT PT138350194T patent/PT2892535T/pt unknown
- 2013-08-30 WO PCT/US2013/057432 patent/WO2014039375A1/en active Application Filing
- 2013-08-30 HR HRP20211817TT patent/HRP20211817T1/hr unknown
- 2013-08-30 JP JP2015530072A patent/JP2015527374A/ja active Pending
- 2013-08-30 US US14/422,182 patent/US20150216868A1/en not_active Abandoned
-
2015
- 2015-08-03 HK HK15107423.5A patent/HK1206642A1/xx unknown
-
2016
- 2016-10-13 AU AU2016244279A patent/AU2016244279B2/en active Active
-
2017
- 2017-04-05 US US15/479,663 patent/US20170202842A1/en not_active Abandoned
- 2017-11-10 JP JP2017216933A patent/JP6511117B2/ja active Active
-
2018
- 2018-08-07 US US16/056,702 patent/US20180338979A1/en not_active Abandoned
-
2019
- 2019-04-05 JP JP2019072361A patent/JP6684941B2/ja active Active
- 2019-10-28 US US16/664,978 patent/US10869869B2/en active Active
-
2020
- 2020-11-11 US US17/095,200 patent/US20210060021A1/en not_active Abandoned
-
2021
- 2021-12-15 CY CY20211101105T patent/CY1124812T1/el unknown
-
2022
- 2022-12-07 US US18/062,764 patent/US20230330091A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2024202233A1 (en) | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same | |
BR112015004578A2 (pt) | métodos para fornecer tratamento adjuvante a um paciente com uma diagnose anterior de melanoma que foi ressectado e para aumentar sobrevivência sem recaída (rfs) de um paciente depois de ressecção de melanoma, e, composição | |
CY1122628T1 (el) | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
ECSP12011834A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos. | |
UY33370A (es) | Composiciones farmacéuticas comprendiendo un fármaco inhibidor de la DPP4 y de la pioglitazona, procedimientos de preparación y utilización | |
UY31747A (es) | Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparacion | |
CR20130043A (es) | Compuestos terapéuticos | |
PH12014501997A1 (en) | Esketamine for the treatment of treatment-refractory or treatment-resistant depression | |
ECSP10010289A (es) | Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada | |
AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
CO6561789A2 (es) | Método de tratamiento | |
CL2017003066A1 (es) | Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal | |
CR20140144A (es) | Derivados de estra-1,3,5 (10), 16-tetraen-3-carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos | |
AR079945A1 (es) | Derivados de pirazina como inhibidores de glucogeno sintasa quinasa 3 (gsk3) | |
TN2009000275A1 (en) | Use of substituted pyranone acid derivatives for the treatment of metabolic syndrome | |
EA201190337A1 (ru) | Способ лечения | |
AR091724A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fampridina, composicion farmaceutica | |
MX2014003867A (es) | Tratamiento de rinitis. | |
WO2013064672A3 (de) | Einmalig dosierte oxazaphosphorine zur therapie von krankheiten | |
CY1114276T1 (el) | Χρηση αιθυλεστερα εικοσαπενταενοϊκου οξεος για θεραπεια υπερτριγλυκεριδαιμιας | |
RU2014105560A (ru) | Терапевтическое средство при переломе кости, которое содержит диоксид углерода в качестве активного ингредиента | |
UA71564U (ru) | Средство для лечения и профилактики урологических заболеваний для перорального применения | |
MY165030A (en) | Treatment of seborrhoea | |
AR081669A1 (es) | Semuloparina para uso como un tratamiento antitrombotico en cirugia ortopedica con perfil beneficio-riesgo mejorado |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: GLAXO GROUP LIMITED (GB) |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS PHARMA AG (CH) |
|
B25A | Requested transfer of rights approved |
Owner name: NOVARTIS AG (CH) |
|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2529 DE 25-06-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |